熱門資訊> 正文
礼来公司上市前库存为即将推出的减肥药带来希望
2025-02-21 02:53
- Eli Lilly (NYSE:LLY) has raised expectations for its experimental weight loss pill, orforglipron, capitalizing $548.1M in pre-launch inventory in 2024 for the next-gen drug ahead of a potential regulatory nod next year.
- The line item indicated in the Indiana-based drugmaker’s 10-K filing on Wednesday reflects LLY's high hopes for the once-daily GLP-1 receptor agonist, a partnership between the company and Japanese pharma Chugai Pharmaceutical (OTCPK:CHGCF) (OTCPK:CHGCY).
- “When we believe that future commercialization is probable and the future economic benefit is expected to be realized, we capitalize pre-launch inventory prior to regulatory approval,” LLY said.
- Several late-stage trials for orforglipron are currently underway. Its ATTAIN-1 and ATTAIN-2 trials are scheduled to read out in Q3 2025, forming the basis for the company’s regulatory filings anticipated in late 2025 ahead of a potential regulatory nod in 2026 for obesity.
More on Eli Lilly
- Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
- Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight
- Eli Lilly and Company (LLY) Q4 2024 Earnings Call Transcript
- Lilly's next obesity drug serves up dramatic weight loss -- and side effects: report
- Eli Lilly files for mixed shelf offering
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
